In 2008, Allon reported Phase IIa results showing that the same product had a positive impact on memory function in patients with mild cognitive impairment, a precursor of Alzheimer's disease.
Allon was set up based on technology developed by Prof. Illana Gozes at the Weizmann Institute of Science and Tel Aviv University. The company has a market cap of $47.6 million. One of the main shareholders is the entrepreneur Efi Gildor.
The company claims that most existing schizophrenia treatments are aimed at preventing the psychotic attacks associated with the illness.
To see more of the Globes or to subscribe to the newspaper, go to http://www.globes-online.com. Copyright (c) 2009, Globes, Tel Aviv, Israel Distributed by McClatchy-Tribune Information Services. For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index